Combination of c-reactive protein and squamous cell carcinoma antigen in predicting postoperative prognosis for patients with squamous cell carcinoma of the esophagus

Ji-Feng Feng\textsuperscript{1,2}, Sheng Chen\textsuperscript{1,2} and Xun Yang\textsuperscript{1,2}

\textsuperscript{1}Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China
\textsuperscript{2}Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou 310022, China

\textbf{Correspondence to:} Xun Yang, \textit{email:} Xunyangzj@sina.com

\textbf{Keywords:} esophageal squamous cell carcinoma (ESCC), c-reactive protein (CRP), squamous cell carcinoma antigen (SCC), cancer-specific survival (CSS), prognosis

\textbf{Received:} March 27, 2017 \hspace{1cm} \textbf{Accepted:} May 08, 2017 \hspace{1cm} \textbf{Published:} June 27, 2017

\textbf{Copyright:} Feng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

\section*{ABSTRACT}

\textbf{Background:} We initially proposed a useful and novel prognostic model, named \textit{CCS} [Combination of c-reactive protein (CRP) and squamous cell carcinoma antigen (SCC)], for predicting the postoperative survival in patients with esophageal squamous cell carcinoma (ESCC).

\textbf{Methods:} Two hundred and fifty-two patients with resectable ESCC were included in this retrospective study. A logistic regression was performed and yielded a logistic equation. The CCS was calculated by the combined CRP and SCC. The optimal cut-off value for CCS was evaluated by X-tile program. Univariate and multivariate analyses were used to evaluate the predictive factors. In addition, a novel nomogram model was also performed to predict the prognosis for patients with ESCC.

\textbf{Results:} In the current study, CCS was calculated as CRP+6.33 SCC according to the logistic equation. The optimal cut-off value was 15.8 for CCS according to the X-tile program. Kaplan-Meier analyses demonstrated that high CCS group had a significantly poor 5-year cancer-specific survival (CSS) than low CCS group (10.3\% vs. 47.3\%, \textit{P}<0.001). According to multivariate analyses, CCS (\textit{P}=0.004), but not CRP (\textit{P}=0.466) or SCC (\textit{P}=0.926), was an independent prognostic factor. A nomogram could be more accuracy for CSS (Harrell’s c-index: 0.70).

\textbf{Conclusion:} The CCS is a useful and independent predictive factor in patients with ESCC.

\section*{INTRODUCTION}

Esophageal cancer (EC) is one of the most fatal types of cancer, leading to over 406,800 deaths worldwide and more than 200,000 deaths in China annually [1, 2]. The histological types are different between China and western countries [3]. Esophageal squamous cell carcinoma (ESCC) is the predominant pathological type in China, which covers more than 90\% of all EC cases [3, 4]. Radical esophagectomy remains the treatment of choice for localized disease, however, the prognosis is still poor [5].

It has increasingly been recognized that inflammation plays a critical role in cancer [6, 7]. Serum c-reactive protein (CRP) is a sensitive biomarker for inflammation. Recent studies revealed that CRP was associated with prognosis in several cancers [8-10]. However, the prognostic role of CRP in EC is still controversial [11-14]. As we know, CRP is influenced by various non-cancer related conditions. In addition, anti-inflammatory medicines and/or other medications may also potentially affect the level of serum CRP.

Serum tumor markers play a key role in cancer diagnosis and prognosis. Therefore, in order to improve the survival time for cancer patients, it is essential to explore relevant tumor markers in various cancers. Squamous cell carcinoma antigen (SCC) is a tumor marker
for squamous cell carcinoma [15]. Recently, SCC is also widely used in a variety of cancers, such as cervical cancer and head and neck cancer [16, 17]. Nevertheless, to date, few data regarding SCC in patients with EC are available, and its role remains controversial [18-20].

As we know, both CRP and SCC may influenced by various non-cancer related conditions, and combination of CRP and SCC could therefore minimise the potential basis. Therefore, we initially proposed a useful and novel prognostic model, named CCS (Combination of CRP and SCC), for predicting the prognosis for patients with ESCC. To the best of our knowledge, no study so far has evaluated the prognostic value of CCS in other cancers as well as ESCC, which makes our study the first of its kind. In addition, we attempt to establish a predictive nomogram to predict the survival prediction in patients with ESCC.

RESULTS

Of the total number of patients, 37 (14.7%) were women and 215 (85.3%) were men. The mean age was 58.5 ± 8.2 years (range 36-80). The logistic regression equation was defined as follow: Y=0.101CRP+0.639SCC-0.686. Thus, CCS=CRP+0.639/0.101SCC=CRP+6.33 SCC. The optimal cut-off value for CCS was 15.8 according to the X-tile program (Figure 1). The relationships between CCS and clinical characteristics were shown in Table 1.

Kaplan-Meier analyses demonstrated that high CCS group had a significantly poor 5-year CSS than low CCS group (10.3% vs. 47.3%, \( P < 0.001 \)) (Figure 2). Multivariate analyses revealed that CCS (\( P =0.004 \)), but not CRP (\( P =0.466 \)) or SCC (\( P =0.926 \)), was an independent prognostic factor (Table 2). In addition, T stage (\( P =0.045 \)) and N stage (\( P <0.001 \)) were also significant independent predictors for CSS (Table 2).

The areas under the curve (AUC) was 0.699 (95% CI: 0.635-0.763, \( P <0.001 \)) for CCS, 0.659 (95% CI: 0.591-0.727, \( P <0.001 \)) for CRP and 0.645 (95% CI: 0.574-0.716, \( P <0.001 \)) for SCC, respectively (Figure 3).

Although the discrimination ability of the CCS was higher than CRP or SCC, the Z tests revealed that there were no significant differences for each other (CCS vs CRP, \( Z=1.428, P=0.153 \); CCS vs SCC, \( Z=1.912, P=0.056 \); CRP vs SCC, \( Z=0.278, P=0.781 \)). The results demonstrated that the CCS predicts survival similar to CRP or SCC. However, multivariate analyses revealed that CCS (\( P =0.004 \)), but not CRP (\( P =0.466 \)) or SCC (\( P =0.926 \)), was an independent prognostic factor.

To predict the risk for patients with ESCC, a novel nomogram model was established by independent prognostic factors, including T stage, N stage and CCS, combined with age and sex (Figure 4). It can predict the probability of death for patients with ESCC. The Harrell’s c-index for CSS prediction was 0.70.

DISCUSSION

To our knowledge, this is the first study to evaluate the prognostic role of CCS (combination of CRP and SCC) in predicting prognosis for patients with resectable ESCC. In the present study, a novel prognostic model (CCS) was conducted based on CRP and SCC and was shown to be an independent predictor for patients with resectable ESCC.

Recently, Camp et al. [21] initial developed a graphical method, named X-tile plot, to illustrate a method of dividing a single cohort into training and validation subsets. They concluded that the X-tile plot can present a new tool for the assessment of biological relationships and discover cut-points based on marker expression. In the current study, the optimal cut-off value for CCS was calculated by a X-tile program, which was 15.8 (Figure 1). Then patients were divided into two groups. The results demonstrated that high CCS group had a significantly poor 5-year CSS than low CCS group (10.3% vs. 47.3%, \( P <0.001 \)).

It has increasingly been recognized that inflammation plays a critical role in cancer. CRP is an acute phase protein with systemic inflammation. More and more...
Table 1: The relationship between CCS and clinical characteristics in ESCC patients

|                      | Cases (n) | CCS ≤ 15.8 (n, %) | CCS > 15.8 (n, %) | P-value |
|----------------------|-----------|--------------------|--------------------|---------|
| **Age (years)**      |           |                    |                    |         |
| ≤ 60                 | 151       | 105 (63.6)         | 46 (52.9)          | 0.097   |
| > 60                 | 101       | 60 (36.4)          | 41 (47.1)          |         |
| **Gender**           |           |                    |                    | 0.158   |
| Female               | 37        | 28 (17.0)          | 9 (10.3)           |         |
| Male                 | 215       | 137 (83.0)         | 78 (89.7)          |         |
| **Tumor length (cm)**|           |                    |                    | 0.016   |
| ≤ 5.0                | 188       | 131 (79.4)         | 57 (65.5)          |         |
| > 5.0                | 64        | 34 (20.6)          | 30 (34.5)          |         |
| **Tumor location**   |           |                    |                    | 0.297   |
| Upper                | 17        | 11 (6.7)           | 6 (6.9)            |         |
| Middle               | 117       | 71 (43.0)          | 46 (52.9)          |         |
| Lower                | 118       | 83 (50.3)          | 35 (40.2)          |         |
| **Vessel invasion**  |           |                    |                    | 0.089   |
| Negative             | 203       | 138 (83.6)         | 65 (74.7)          |         |
| Positive             | 49        | 27 (16.4)          | 22 (25.3)          |         |
| **Perineural invasion**|         |                    |                    | 0.067   |
| Negative             | 204       | 139 (84.2)         | 65 (74.7)          |         |
| Positive             | 48        | 26 (15.8)          | 22 (25.3)          |         |
| **Differentiation**  |           |                    |                    | 0.114   |
| Well                 | 37        | 26 (15.8)          | 11 (12.6)          |         |
| Moderate             | 156       | 107 (64.8)         | 49 (56.3)          |         |
| Poor                 | 59        | 32 (19.4)          | 27 (31.1)          |         |
| **T stage**          |           |                    |                    | <0.001  |
| T1-2                 | 94        | 77 (46.7)          | 17 (19.5)          |         |
| T3-4                 | 158       | 88 (53.3)          | 70 (80.5)          |         |
| **N stage**          |           |                    |                    | 0.024   |
| N0                   | 146       | 104 (63.0)         | 42 (48.3)          |         |
| N1-3                 | 106       | 61 (37.0)          | 45 (51.7)          |         |
| **CRP (mg/L)**       |           |                    |                    | <0.001  |
| ≤ 10.0               | 180       | 154 (93.3)         | 26 (29.9)          |         |
| > 10.0               | 72        | 11 (6.7)           | 61 (70.1)          |         |
| **SCC (ng/ml)**      |           |                    |                    | <0.001  |
| ≤ 1.50               | 179       | 140 (84.8)         | 39 (44.8)          |         |
| > 1.50               | 73        | 25 (15.2)          | 48 (55.2)          |         |

ESCC=esophageal squamous cell carcinoma; CCS=combination of CRP and SCC; CRP= c-reactive protein; SCC= squamous cell carcinoma antigen

Statistical methods: The Pearson Chi squared test.
studies demonstrated that serum CRP is associated with prognosis in several cancers, including EC [8-10, 13, 14]. Recently, we conducted a meta-analysis revealed that CRP were significantly correlated with survival in patients with EC [22]. In our study, patients with CRP ≤10.0 mg/L had a significantly better 5-year CSS than patients with CRP >10.0 mg/L (41.7% vs. 16.7%, \( P < 0.001 \)). However, CRP was not an independent prognostic factor in multivariate analyses (\( P = 0.466 \)). SCC is a tumor marker for squamous cell carcinoma. However, the role for SCC in patients with EC remains controversial [18-20]. A meta-analysis revealed that elevated SCC do not be associated with poor survival [23]. In our study, patients with SCC ≤1.5 ng/ml had a significantly better 5-year CSS than patients with SCC >1.5 ng/ml (38.0% vs. 26.0%, \( P = 0.014 \)). However, multivariate Cox regression model revealed SCC was still not an independent prognostic factor (\( P = 0.926 \)).

Recently, Chen et al. [24] demonstrated that SCC and CRP as prognostic biomarkers in recurrent oral cavity squamous cell carcinoma. They revealed that patients with the high levels of SCC and CRP had a significantly worse overall survival. This observation is in line with data from our study. In our study, however, multivariate Cox regression model revealed neither SCC nor CRP was independent prognostic factor. The other biomarker called ADAR1 has been discussed as a potential new biomarker for ESCC [25]. ADAR1, also known as RNA editase, has attracted increasing attention in recent years. They concluded that over-expressed ADAR1 correlates to shorter survival time of ESCC patients. It has been reported that interferons induce the upregulation of ADAR1 [26], therefore raising the possibility that ADAR1 serves as an antiviral defense mechanism against inflammation. However, in comparison with the ADAR1, the CCS is easy to measure routinely because of its low cost and convenience.

As we know, both CRP and SCC may influenced by various non-cancer related conditions, and combination of CRP and SCC could therefore minimise the potential basis. Therefore, we initially proposed a useful and novel prognostic model (CCS) in patients with ESCC. In our study, CCS (\( P = 0.004 \)), but not CRP (\( P = 0.466 \)) or SCC (\( P = 0.926 \)), was an independent prognostic biomarker. Additionally, we showed a better discrimination for CCS in terms of HR than CRP and SCC. From this point of view, the CCS may have additional prognostic value over the CRP or SCC with regard to predicting CSS in ESCC patients.

It is widely agreed that T stage and N stage are strong, independent prognostic factors in patients with EC. Due to the relatively small number of patients, we divided the patients into two groups regarding T stage (T1-2 vs T3-4) and N stage (N0 vs. N1-3) like previous published articles [27-29]. In our study, we also demonstrated that T stage (\( P = 0.045 \)) and N stage (\( P < 0.001 \)) were independent prognostic factors.

It is well know that nomogram could establish a simple and graphic representation of a statistical predictive

![Figure 2: Kaplan-Meier CSS curves stratified by CCS.](image-url)Patients with CCS ≤15.8 had a significantly better 5-year CSS than patients with CCS >15.8 (47.3% vs. 10.3%, \( P < 0.001 \)).
In the current study, therefore, we attempt to establish a predictive nomogram model to predict the probability that the death risk for ESCC patients based on T stage, N stage and CCS combined with age and sex. The nomogram performed well in predicting CSS by c-index (0.70).

The potential limitations of the present study include the use of a retrospective analysis and the relatively small number of patients. Furthermore, in our study, we excluded patients who had received neoadjuvant treatment, which may have influenced the result. In addition, our study revealed that CCS is an independent factor, however, it should be kept in mind that CCS itself alone without other variables may not associate with prognosis. Therefore, larger prospective studies will need to be performed to confirm these preliminary results.

In summary, the CCS is a useful and independent predictive factor in patients with ESCC. Based on the results of our study, we believe that CCS was superior to CRP or SCC as a more precise prognostic biomarker in ESCC.

### Table 2: Univariate and multivariate analyses in ESCC patients

|                          | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                          | HR (95% CI)         | P-value               | HR (95% CI)      | P-value                |
| Age (years)              |                     | 0.967                 | -                | -                      |
| >60 vs. ≤60              | 1.007 (0.737-1.376) | -                     | -                |                        |
| Gender                   | 0.138               | -                     | -                |                        |
| male vs. female          | 1.425 (0.892-2.274) | -                     | -                |                        |
| Tumor length (cm)        |                     | 0.292                 | -                | -                      |
| >5.0 vs. ≤5.0            | 1.204 (0.852-1.700) | -                     | -                |                        |
| Tumor location           |                     | 0.379                 | -                | -                      |
| lower vs. upper/middle    | 1.120 (0.870-1.442) | -                     | -                |                        |
| Vessel invasion          | 0.002               | 0.742                 | -                |                        |
| positive vs. negative    | 1.752 (1.225-2.504) | 1.068 (0.722-1.579)   | -                |                        |
| Perineural invasion      | 0.018               | 0.957                 | -                |                        |
| positive vs. negative    | 1.553 (1.079-2.233) | 1.011 (0.682-1.499)   | -                |                        |
| Differentiation          | 0.060               | -                     | -                |                        |
| poor vs. well/moderate   | 1.278 (0.989-1.650) | -                     | -                |                        |
| T stage                  | <0.001              | 0.045                 | -                |                        |
| T3-4 vs. T1-2            | 2.193 (1.559-3.087) | 1.472 (1.009-2.149)   | -                |                        |
| N stage                  | <0.001              | <0.001                | -                |                        |
| N1-3 vs. N0              | 2.671 (1.957-3.644) | 1.975 (1.385-2.816)   | -                |                        |
| CRP (mg/L)               | <0.001              | 0.466                 | -                |                        |
| >10.0 vs. ≤10.0          | 2.152 (1.563-2.963) | 1.193 (0.743-1.914)   | -                |                        |
| SCC (ng/ml)              | 0.016               | 0.926                 | -                |                        |
| >1.50 vs. ≤1.50          | 1.492 (1.077-2.066) | 0.981 (0.660-1.458)   | -                |                        |
| CCS                      | <0.001              | 0.004                 | -                |                        |
| >15.8 vs. ≤15.8          | 2.853 (2.090-3.896) | 2.092 (1.272-3.441)   | -                |                        |

ESCC=esophageal squamous cell carcinoma; CRP= c-reactive protein; SCC= squamous cell carcinoma antigen; CCS=combination of CRP and SCC; HR=hazard ratio; CI=confidence interval

Statistical methods: Univariate and multivariate analyses.
**Figure 3: ROC curves for CSS prediction.** The AUC was 0.699 (95% CI: 0.635-0.763, \( P < 0.001 \)) for CCS, 0.659 (95% CI: 0.591-0.727, \( P < 0.001 \)) for CRP and 0.645 (95% CI: 0.574-0.716, \( P < 0.001 \)) for SCC, respectively.

**Figure 4: Nomogram model for death risk prediction.** The Harrell’s c-index for CSS prediction was 0.70.
MATERIALS AND METHODS

Between January 2005 and December 2008, a total of 252 patients with resectable ESCC were included in the current retrospective study. The eligibility criteria were included: (1) ESCC was confirmed by histopathological examination; (2) curative surgery with margins histologically free of disease; (3) without preoperative neoadjuvant treatment; (4) without any form of acute infection or chronic inflammatory disease; and (5) preoperative serum CRP and SCC were obtained before surgery within one week. The patients in the current study were staged according to the 7th edition of the American Joint Committee on Cancer Cancer Staging [31]. The study was approved by the Ethics Committees of Zhejiang Cancer Hospital.

The standard surgical approach included the Ivor Lewis and the McKeown procedure. The lymphadenectomy included two-field and three-field lymphadenectomy. In the current study, most of patients underwent two-field lymphadenectomy. Three-field lymphadenectomy was performed only if the cervical lymph nodes were thought to be abnormal. As the role of postoperative adjuvant treatment was controversial during that period, adjuvant therapy was not mandatory. The most frequent adjuvant chemotherapy included 5-fluorouracil and cisplatin and the median postoperative radiation dose was 50 Gy.

Data on preoperative laboratory examination were extracted in our medical records. The serum CRP and SCC were taken within one week prior to surgery. The cut-off value for CRP and SCC were 10 mg/L and 1.5 ng/ml according to the previous studies [13, 14, 20]. The CCS was calculated by combined CRP and SCC according to the logistic equation. In the current study, a cancer-specific survival (CSS) analysis was ascertained. The last follow-up was 30 June 2013.

Statistical analysis

The optimal cut-off value for CCS was calculated by a X-tile program [21]. The Pearson Chi squared test was used to determine the significance of differences for dichotomous variables. Kaplan-Meier methods were used to analyse CSS. Univariate and multivariate analyses were performed to analyse the prognostic factors. A receiver operating characteristic (ROC) curve for survival prediction was plotted to verify the CSS prediction. The area under curve (AUC) was used as an estimation of diagnostic accuracy. A Z test was performed to compare the significant differences for CCS, CRP and SCC. A nomogram model was also established and the predictive accuracy was evaluated by Harrell’s concordance index (c-index) [32]. Statistical analyses were conducted with SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and R 3.2.3 software (Institute for Statistics and Mathematics, Vienna, Austria).

Authors’ contributions

JFF and XY conceived this study, collected data, performed analysis and drafted the manuscript. SC participated in study design, literature search and coordination. All authors read and approve the final manuscript.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5-29.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-2917.
3. Napier KJ, Scheerer M, Misra S. Esophageal cancer: A review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014; 6: 112-120.
4. Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M, Tanaka H. Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 2013; 23: 233-242.
5. Tachibana M, Kinugasa S, Hirahara N, Yoshimura H. Lymph node classification of esophageal squamous cell carcinoma and adenocarcinoma. Eur J Cardiothorac Surg. 2008; 34: 427-431.
6. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357: 539-545.
7. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454: 436-444.
8. Shimura T, Kitagawa M, Yamada T, Ebi M, Mizoshita T, Tanida S, Kataoka H, Kamiya T, Joh T. C-reactive protein is a potential prognostic factor for metastatic gastric cancer. Anticancer Res. 2012; 32: 491-496.
9. Nozoe T, Iguchi T, Adachi E, Matsukuma A, Ezaki T. Preoperative elevation of serum c-reactive protein as an independent prognostic indicator for gastric cancer. Surg Today. 2011; 41: 510-513.
10. Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer. 2007; 110: 1241-1247.
11. Wei XL, Wang FH, Zhang DS, Qiu MZ, Ren C, Jin Y, Zhou YX, Wang DS, He MM, Bai L, Wang F, Luo HY, Li YH, et al. A novel inflammation-based prognostic score
in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. BMC Cancer. 2015; 15: 350.

12. Nozoe T, Saeki H, Sugimachi K. Significance of pre-operative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001; 182: 197-201.

13. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S, Ochiai T. Elevation of pre-operative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2003; 83: 248-252.

14. Zingg U, Forberger J, Rajcic B, Langton C, Jamieson GG. Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg. 2010; 14: 462-469.

15. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 1977; 40: 1621-1628.

16. Bolger BS, Dabbas M, Lopes A, Monaghan JM. Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecol Oncol. 1997; 65: 309-313.

17. Molina R, Torres MD, Moragas M, Perez-Villa J, Filella X, Jo J, Farrus X, Gimenez N, Traserra J, Ballesta AM. Prognostic significance of SCC antigen in the serum of patients with head and neck cancer. Tumour Biol. 1996; 17: 81-89.

18. Cao M, Yie SM, Wu SM, Chen S, Lou B, He X, Ye SR, Xie K, Rao L, Gao E, Ye NY. Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis. 2009; 26: 751-758.

19. Kosugi S, Nishimaki T, Kanda T, Nakagawa S, Ohashi M, Hatakeyama K. Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg. 2004; 28: 680-685.

20. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, Kobayashi S, Hayashi H, Ochiai T. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery. 2003; 133: 486-494.

21. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10: 7252-7259.

22. Huang Y, Feng JF, Liu JS, Chen QX. Prognostic role of serum C-reactive protein in esophageal cancer: a systematic review and meta-analysis. Ther Clin Risk Manag. 2015; 11: 89-94.

23. Chen M, Huang J, Zhu Z, Zhang J, Li K. Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer. 2013; 13: 539.

24. Chen IH, Liao CT, Wang HM, Huang JJ, Kang CJ, Huang SF. Using SCC antigen and CRP levels as prognostic biomarkers in recurrent oral cavity squamous cell carcinoma. PLoS One. 2014; 9: e105326.

25. Qiao JJ, Chan TH, Qin YR, Chen L. ADAR1: a promising new biomarker for esophageal squamous cell carcinoma? Expert Rev Anticancer Ther. 2014; 14: 865-868.

26. Patterson JB, Samuel CE. Expression and regulation by interferon of a doublestranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol Cell Biol. 1995; 15: 5376-5388.

27. Nakamura M, Iwahashi M, Nakamori M, Ojima T, Katsuda M, Iida T, Hayata K, Kato T, Yamaue H. New prognostic score for the survival of patients with esophageal squamous cell carcinoma. Surg Today. 2014; 44: 875-883.

28. Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, Mori M, Doki Y. Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. Exp Ther Med. 2011; 2: 879-885.

29. Guillem P, Triboulet JP. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus. 2005; 18: 146-150.

30. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008; 26: 1364-1370.

31. Rice TW, Rusch VW, Ishwaran H, Blackstone EH, Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Staging Manuals. Cancer. 2010; 116: 3763-3773.

32. Harrell FE. Regression modeling strategies. New York: Springer. 2001.